Market Overview

Affymax Shares are Trading near Liquidation Value; Analyst Report by BrokerBank Securities, Inc.


NEW YORK, June 30, 2014 /PRNewswire/ -- According to the National Kidney Foundation, chronic kidney disease affects over 26 million adults in the U.S., and is caused by diabetes and high blood pressure.  As kidney functions deteriorate, the kidney's ability to produce red blood cells declines, and results in anemia.  Anemia is a condition in which the patient's blood is deficient in red blood cells and hemoglobin.  Kidney dialysis is expensive, and the cost of anemia drugs has been Medicare's single largest drug expenditure, amounting to $3.9 billion in 2007.

Affymax, Inc. (OTCQB: AFFY) is a biopharmaceutical company that was formed to discover, develop and deliver innovative therapies for patients with serious diseases, including kidney disease.  Affymax has developed Omontys (also known as peginesatide), an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.  When introduced, it was the only once-monthly ESA available to the adult dialysis patient population in the U.S. The potential market for this product is significant, as most patients receiving dialysis eventually develop anemia. 

A full in-depth analyst report on AFFY that includes company overview, product pipeline, market and competition breakdown, recent events, outlook, analyst summary, and recommendation can be viewed by using the following link at no cost:

Copy and paste to browser may be required.

This report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this report have not been compensated in any form.  A full disclaimer can be found by viewing the full analyst report.


This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein. 


Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Charles I. Reed, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at